Novel agents targeting immune checkpoints and costimulatory receptors, such as LAG‐3, OX40, HLA‐E, and 4‐1BB, are currently evaluated in clinical trials for HNSCC. This evidence concerns the gene LAG3 and head and neck squamous cell carcinoma.